



ALPHA IVF GROUP BERHAD

Registration No. 202101005100 (1405399-X)

**ALPHA IVF GROUP BERHAD
AND ITS SUBSIDIARIES**

**CONDENSED CONSOLIDATED
INTERIM FINANCIAL REPORT
FOR THE SECOND QUARTER ENDED
30 NOVEMBER 2024**

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME FOR THE SECOND QUARTER ENDED 30 NOVEMBER 2024**

	Note	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		30.11.2024 RM'000	30.11.2023 RM'000	30.11.2024 RM'000	30.11.2023 RM'000
Revenue	A9	43,244	38,542	86,239	80,138
Cost of sales		(16,936)	(16,634)	(34,253)	(34,363)
Gross profit		26,308	21,908	51,986	45,775
Other income		1,663	575	3,259	1,025
Administrative expenses		(7,056)	(5,017)	(14,563)	(9,730)
Other expenses		(511)	(573)	(1,022)	(2,063)
Finance costs		(218)	(253)	(474)	(423)
Profit before taxation ("PBT")	B12	20,186	16,640	39,186	34,584
Income tax expense	B6	(4,907)	(4,181)	(8,964)	(8,603)
Profit after taxation ("PAT")		15,279	12,459	30,222	25,981
Other comprehensive income					
<u>Item that will be reclassified subsequently to profit or loss</u>					
Foreign currency translation differences		(11)	135	(434)	97
Total comprehensive income		15,268	12,594	29,788	26,078
Profit after taxation attributable to:					
Owners of the Company		15,100	12,214	29,481	25,336
Non-controlling interests		179	245	741	645
		15,279	12,459	30,222	25,981
Total comprehensive income attributable to:					
Owners of the Company		15,081	12,317	29,138	25,410
Non-controlling interests		187	277	650	668
		15,268	12,594	29,788	26,078
Earnings per share attributable to Owners of the Company					
Basic/Diluted (sen) ⁽¹⁾	B11	0.31	0.27	0.61	0.56

Note:

(1) The basic and diluted earnings per share of the Company are computed based on Profit After Taxation attributable to the owners of the Company divided by the number of ordinary shares of the Company referred to in Note B11. The Group has not issued any dilutive potential ordinary shares and hence, the diluted earnings per share is equal to the basic earnings per share.

The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the audited financial statements for the financial year ended 31 May 2024 and the accompanying explanatory notes attached to this interim financial report.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 NOVEMBER 2024

	Unaudited	Audited
	As at	As at
	30.11.2024	31.5.2024
	RM'000	RM'000
ASSETS		
Non-Current Assets		
Equipment	9,852	9,121
Right-of-use assets	13,487	14,944
Other investments	30,646	30,758
Goodwill	8,931	8,931
Deferred tax assets	1,978	1,977
	64,894	65,731
Current Assets		
Inventories	3,284	2,935
Trade receivables	1,190	966
Other receivables, deposits and prepayments	9,012	7,312
Short-term investments	128,844	128,416
Cash and bank balances	26,247	22,906
	168,577	162,535
TOTAL ASSETS	233,471	228,266
EQUITY AND LIABILITIES		
Share capital	119,753	119,753
Retained profits	52,229	44,618
Reorganisation reserve	22,499	22,499
Foreign exchange translation reserve	221	564
Equity attributable to owners of the Company	194,702	187,434
Non-controlling interests	2,996	2,346
Total Equity	197,698	189,780
Non-Current Liabilities		
Lease liabilities	12,545	13,394
Provision for restoration costs	1,089	1,091
	13,634	14,485
Current Liabilities		
Trade payables	1,946	2,518
Other payables and accruals	4,803	6,595
Contract liabilities	7,363	6,777
Lease liabilities	2,147	2,686
Current tax liabilities	5,880	5,425
	22,139	24,001
Total Liabilities	35,773	38,486
TOTAL EQUITY AND LIABILITIES	233,471	228,266
Net assets per ordinary share attributable to Owners of the Company (RM)	0.04	0.04

The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the financial year ended 31 May 2024 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD
Registration No.: 202101005100 (1405399-X)
(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE SECOND QUARTER ENDED 30 NOVEMBER 2024**

	Share Capital	Reorganisation Reserve	Foreign Exchange Translation Reserve	Retained Profits	Attributable to Owners of the Company	Non- Controlling Interests	Total Equity
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
As at 1 June 2024	119,753	22,499	564	44,618	187,434	2,346	189,780
Profit after taxation for the financial period	-	-	-	29,481	29,481	741	30,222
Other comprehensive income for the financial period:							
- Foreign currency translation differences	-	-	(343)	-	(343)	(91)	(434)
Total comprehensive income for the financial period	-	-	(343)	29,481	29,138	650	29,788
Dividends:							
- by the Company	-	-	-	(21,870)	(21,870)	-	(21,870)
As at 30 November 2024	119,753	22,499	221	52,229	194,702	2,996	197,698

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the audited financial statements for the financial year ended 31 May 2024 and the accompanying explanatory notes attached to this interim financial report.

ALPHA IVF GROUP BERHAD

Registration No.: 202101005100 (1405399-X)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SECOND QUARTER ENDED 30 NOVEMBER 2024**

	<u>Period Ended</u> 30.11.2024 RM'000	<u>Period Ended</u> 30.11.2023 RM'000
CASH FLOW FROM OPERATING ACTIVITIES		
Profit before taxation	39,186	34,584
Adjustments for:		
Depreciation of equipment	1,216	2,317
Depreciation of right-of-use assets	1,368	1,400
Interest expense	474	423
Equipment written off	-	#
Loss on disposal of equipment	1	#
Interest income	(2,949)	(926)
Operating profit before working capital changes	<u>39,296</u>	<u>37,798</u>
Changes in working capital:		
Inventories	(365)	(272)
Trade and other receivables	(1,986)	(349)
Trade and other payables	(2,262)	376
Contract Liabilities	612	494
CASH FROM OPERATIONS	<u>35,295</u>	<u>38,047</u>
Income tax paid	(8,445)	(5,734)
NET CASH FROM OPERATING ACTIVITIES	<u>26,850</u>	<u>32,313</u>
CASH FLOW FROM INVESTING ACTIVITIES		
Proceeds from disposal of equipment	-	#
Interest income	2,949	926
Purchase of equipment	(2,006)	(3,439)
NET CASH FROM/(FOR) INVESTING ACTIVITIES	<u>943</u>	<u>(2,513)</u>
CASH FLOW FROM FINANCING ACTIVITIES		
Dividend paid by the Company	(21,870)	(8,167)
Dividend paid by a subsidiary to non-controlling interests	-	(1,039)
Interest paid	(349)	(397)
Repayment of term loans	-	(4,349)
Repayment of lease liabilities	(1,297)	(1,126)
NET CASH FOR FINANCING ACTIVITIES	<u>(23,516)</u>	<u>(15,078)</u>
Net increase in cash and cash equivalents	4,277	14,722
Effect of foreign exchange translation	(508)	160
Cash and cash equivalents at beginning of the financial period	<u>151,322</u>	<u>55,582</u>
Cash and cash equivalents at end of the financial period	<u>155,091</u>	<u>70,464</u>

– Less than RM1,000.

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the audited financial statements for the financial year ended 31 May 2024 and the accompanying explanatory notes attached to this interim financial report.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 30 NOVEMBER 2024

A1. Basis of Preparation

The interim financial report of Alpha IVF Group Berhad (“Company”) and its subsidiaries (“Group”) are unaudited and have been prepared in accordance with requirements of Malaysian Financial Reporting Standards (“MFRS”) No. 134: Interim Financial Reporting and Rule 9.22 and Appendix 9B of the Listing Requirements of Bursa Securities.

The interim financial report should be read in conjunction with the audited financial statements for the financial year ended 31 May 2024 as disclosed in the Annual Report 2024 and the accompanying notes attached to this interim financial report.

A2. Summary of Significant Accounting Policies

The significant accounting policies and methods of computation adopted by the Group in this interim financial report are consistent with those adopted in the most recent audited annual financial statements for the year ended 31 May 2024. During the current financial period, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any):

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Amendments to MFRS 16: Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101: Classification of Liabilities as Current or Non-Current	1 January 2024
Amendments to MFRS 101: Non-Current Liabilities with Covenants	1 January 2024
Amendments to MFRS 107 and MFRS 7: Supplier Finance Agreements	1 January 2024

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) did not have any material impact on the Group’s financial statements.

The Group has not applied in advance the following accounting standards and/or interpretations (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standard Board (“MASB”) but are not yet effective for the financial period ended 30 November 2024:

MFRSs and/or IC Interpretations (Including the Consequential Amendments)	Effective Date
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025
Annual Improvements to MFRS Accounting Standards – Volume 11	1 January 2026
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments	1 January 2026
MFRS 18: Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19: Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Deferred

The adoption of the above accounting standards and/or interpretations (including the consequential amendments, if any) is expected to have no material impact on the financial statements of the Group upon its initial application.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 30 NOVEMBER 2024 (CONT'D)

A3. Auditors' Report on preceding Annual Financial Statements

There was no qualification on the audited consolidated financial statements of the Group for the financial year ended 31 May 2024.

A4. Seasonal or cyclical factors

The business operation of the Group has not been materially affected by any unusual seasonal or cyclical factors.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial period-to-date.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect to the Group in the current financial quarter and financial period to-date.

A7. Debt and equity securities

There were no issuance, cancellation, repurchase, resale and repayment of debt and equity securities during the current financial quarter under review.

A8. Dividends Paid

There were no dividends paid by the Company during the current financial quarter. For information, the Company had declared and paid an interim dividend of 0.50 sen per ordinary share on 4,860,000,000 shares in respect of the financial year ending 31 May 2025 amounting to RM24,300,000 on 31 December 2024.

A9. Segmental Reporting

The Group operates predominantly in one business segment i.e. focused only in the business of operating women's specialists centres and provision of medical consultants and specialised medical services. Accordingly, the information by business segments is not presented.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 30 NOVEMBER 2024 (CONT'D)

A9. Segmental Reporting (Cont'd)

Geographical Market

The following table provides an analysis of the Group's revenue by geographical segment:

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	30.11.2024	30.11.2023	30.11.2024	30.11.2023
	RM'000	RM'000	RM'000	RM'000
Revenue				
- Malaysia	37,977	30,435	73,380	64,102
- Singapore	<u>5,267</u>	<u>8,107</u>	<u>12,859</u>	<u>16,036</u>
	<u>43,244</u>	<u>38,542</u>	<u>86,239</u>	<u>80,138</u>

A10. Valuation of Equipment

There was no valuation of equipment in the current financial quarter under review.

A11. Material events subsequent to the end of the current financial quarter

There are no material events subsequent to the end of the current financial quarter that have not been reflected in this interim financial report.

A12. Changes in the composition of the Group

Save as disclose below, there were no changes in the composition of the Group during the current financial quarter under review.

(a) Increase of Issued and Paid-Up Capital of Alpha IVF Systems Sdn Bhd ("AIS")

On 24 October 2024 and 25 November 2024, AIS, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM2,000,100 to RM3,700,000 by way of issuance of 1,699,900 new ordinary shares and from RM3,700,000 to RM13,700,000 by way of issuance of 10,000,000 new ordinary shares each respectively. The Company subscribed for the additional 11,699,900 new ordinary shares at RM1 each.

(b) Increase of Issued and Paid-Up Capital of Alpha IVF International (China) Sdn Bhd ("AIIC")

On 28 October 2024, AIIC, a wholly-owned subsidiary of the Company, increased its issued and paid-up capital from RM600,000 to RM2,000,000 by way of issuance of 1,400,000 new ordinary shares. The Company subscribed for the additional 1,400,000 new ordinary shares at RM1 each.

(c) Subscription of Shares in PT Alpha SPOG Indonesia ("PT SPOG")

On 8 November 2024, AIS and AIWS have subscribed 990,000 and 10,000 new ordinary shares at Indonesian Rupiah 10,000 (approximately RM2.84 and RM2.91) each respectively. An issued and paid-up capital of Indonesian Rupiah 10,000,000,000 (approximately RM2,837,624) comprising of 1,000,000 shares have been injected in PT SPOG.

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 30 NOVEMBER 2024 (CONT'D)

A12. Changes in the composition of the Group (Cont'd)

(d) Subscription of Shares in Alpha International (Shanghai) Medical Consulting Limited (“AISMC”)

On 15 November 2024, AIIC have subscribed 1,011,593 new ordinary shares at Chinese Yuan 1 (approximately RM0.6185). An issued and paid-up capital of Chinese Yuan 1,011,593 (approximately RM625,660) comprising of 1,011,593 shares have been injected in AISMC.

(e) Incorporation of Alpha International (Guangzhou) Medical Consulting Limited (“AIGMC”)

On 22 November 2024, AIIC, a wholly-owned subsidiary of the Company, has incorporated a wholly owned subsidiary, AIGMC, will register share capital of Chinese Yuan 2,240,000 (approximately RM1,379,840 @ Bank Negara Malaysia rate 0.6160). The principal activity of the subsidiary is to operate as sales representative offices in Guangzhou.

(f) Incorporation of Alpha International Women’s Specialists (Johor) Sdn Bhd (“AIWS Johor”)

On 26 November 2024, the Company incorporated a wholly owned subsidiary, AIWS Johor, with issued capital of RM100 comprising 100 ordinary shares. The principal activity of AIWS Johor is to run a women’s specialists centre and as medical consultants.

(g) Incorporation of Alpha IVF (Manila) Incorporated (“AIMI”)

On 9 December 2024, AIS, a wholly-owned subsidiary of the Company with Dato’ Dr. Lee Soon Soo, Dr. Ng Peng Wah, Dr. Romerico F. Torres and Dr. Maria Victoria Tan, have incorporated AIMI, with issued capital of PHP 125,000,000 (equivalent to RM9,533,875), consisting of 125,000,000 shares with a par value of PHP 1.00 each (equivalent to Bank Negara Malaysia rate @ RM0.076271 each) is fully subscribed. Based on the announcement dated 3 September 2024, Dato’ Dr. Lee Soon Soo and Dr. Ng Peng Wah shall be holding the shares in trust for AIS. The principal activity of AIMI is to provide services in Obstetrics & Gynaecology and in Fertility including male infertility in the Philippines, and the principal business of AIMI shall be under the trade name and style of “Alpha IVF & Women’s Specialists (Manila)”.

A13. Contingent Assets and Contingent Liabilities

There were no contingent assets and contingent liabilities as at the date of this interim financial report.

A14. Material capital commitments

Save as disclosed below, there is no material commitment for capital expenditure, which upon becoming enforceable, may have a material effect on the Group’s financial position as at the date of this interim financial report.

	30.11.2024	31.5.2024
	RM'000	RM'000
Purchase of equipment	<u>1,605</u>	<u>271</u>

A. NOTES TO THE INTERIM FINANCIAL REPORT FOR THE QUARTER ENDED 30 NOVEMBER 2024 (CONT'D)

A15. Significant related party transactions

The Group carried out the following significant transactions with related parties during the financial period:

Transacting Parties	Nature of transactions	CURRENT QUARTER ENDED		CUMULATIVE PERIOD ENDED	
		30.11.2024	30.11.2023	30.11.2024	30.11.2023
		RM'000	RM'000	RM'000	RM'000
<u>Significant transactions with Directors of the Company</u>					
(i) Alpha KL and Dato' Dr. Lee Soon Soo ("DDLSS")	Consultancy services provided by DDLSS	(348)	(411)	(647)	(1,035)
(ii) Genesis and Dr. Ng Peng Wah ("DNPW")	Consultancy services provided by DNPW	(677)	(706)	(1,424)	(1,451)
<u>Significant transactions with Directors of the Subsidiaries</u>					
(iii) Alpha KL and Dr. Haris Bin Hamzah ("Dr. Haris")	Consultancy services provided by Dr. Haris	(55)	(95)	(91)	(192)
(iv) Alhaya and Dr. Haris	Consultancy services provided by Dr. Haris	(61)	-	(124)	-
<u>Significant transactions with Related Parties</u>					
(v) Alpha Singapore and Dr. Tan Heng Hao ("Dr. Tan")	Consultancy services provided by Dr. Tan	(1,419)	(2,070)	(3,019)	(3,885)
(vi) Alpha Singapore and Dr. Tan	Administrative fee income charged to Dr. Tan	17	17	43	36
(vii) Alpha KL and Baby Xort Sdn Bhd ("Baby Xort")	Sperm sorting services provided by Baby Xort	(186)	(150)	(302)	(284)

Alpha KL – Alpha International Women's Specialists Sdn Bhd
Alpha Singapore – Alpha International Women's Specialists (Singapore) Pte Ltd
Genesis – Genesis Specialists Sdn Bhd
Alhaya – Alhaya International Women's Specialists Sdn Bhd

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA SECURITIES

B1. Review of Performance

(a) Results for current quarter

The Group recorded a revenue of RM43.24 million for the current financial quarter ended 30 November 2024 which represented an increase of RM4.70 million or 12.20% as compared to the recorded revenue of RM38.54 million for the preceding year corresponding quarter ended 30 November 2023. The Group's revenue was principally derived from the provision of assisted reproductive services focusing on in-vitro fertilisation ("IVF") treatments. The increase in revenue mainly contributed from foreign patients.

The Group recognised a profit before taxation of RM20.19 million and profit after taxation of RM15.28 million respectively for the current financial quarter compared to profit before taxation of RM16.64 million and profit after taxation of RM12.46 million respectively for the preceding year corresponding quarter ended 30 November 2023. The increased in profit before taxation and profit after taxation were aligned with the growth in sales revenue for the current financial quarter ended 30 November 2024.

(b) Results for financial period-to-date

The Group recorded a revenue of RM86.24 million for the current financial period-to-date ended 30 November 2024 which represented an increase of RM6.1 million or 7.61% from RM80.14 million as compared to the preceding corresponding period-to-date ended 30 November 2023 mainly due to higher sales revenue from foreign patients. The Group's revenue was principally derived from the provision of assisted reproductive services focusing on IVF treatments.

In line with the above, the Group recognised a profit before taxation of RM39.19 million and profit after taxation of RM30.22 million respectively for the current financial period-to-date, representing an increase of RM4.61 million in profit before taxation and RM4.24 million in profit after taxation respectively as compared to the preceding corresponding period-to-date ended 30 November 2023.

B2. Comparison with immediate preceding quarter's results

On a quarter-on-quarter basis, the Group recorded a revenue of RM43.24 million, which is 0.56% higher when compared to its immediate preceding quarter of RM43.00 million.

In line with the above, the Group recorded a higher profit before taxation of RM20.19 million in the current financial quarter ended 30 November 2024, representing an increase of RM1.19 million or 6.26% as compared to RM19.00 million in the immediate preceding quarter ended 31 August 2024.

B3. Prospects

Our Group's strategies are to continue with our existing business and leverage on our core competency in IVF to expand our business both locally and regionally by implementing the following:

- (i) To continue expanding our specialist services in Malaysia, China and South East Asia.
- (ii) To expand and upgrade existing specialist centres and facilities.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B3. Prospects (Cont'd)

- (iii) To carry out marketing activities to promote our services while at the same time, increase the market awareness of our Group and generate sales leads for our business in Malaysia and foreign markets.
- (iv) To expand our research & development ("R&D") including expansion of R&D team to keep up to date with the latest development in assisted reproductive services to support the growth of the Group's business.

The Group believes that its prospects in the assisted reproductive service industry are favourable in view of our competitive strengths as set out in Section 7.3 of the Prospectus, the Group's business strategies as set out above as well the industry overview as set out in Section 8 of the Prospectus.

B4. Profit forecast or profit guarantee

The Group did not issue any profit forecast or profit guarantee in any public document in respect of the interim financial reporting period under review.

B5. Status of corporate proposals

Save as disclosed in A11, there were no corporate proposals announced but not completed as at the date of this interim financial report.

B6. Income tax expense

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	30.11.2024	30.11.2023	30.11.2024	30.11.2023
	RM'000	RM'000	RM'000	RM'000
Income tax expense				
- Current year	4,907	4,157	8,966	8,579
- Prior year	-	14	-	14
Deferred tax expense				
- Current year	#	(83)	(2)	(83)
- Prior year	-	93	-	93
	<u>4,907</u>	<u>4,181</u>	<u>8,964</u>	<u>8,603</u>
Effective tax rate (%)	24%	25%	23%	25%

– Less than RM1,000.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B7. Utilisation of Proceeds from the IPO

The gross proceeds raised from the Public Issue is RM116.64 million and the status of the utilisation of proceeds as at 30 November 2024 is as follows:

Details of utilisation ⁽¹⁾	Initial	After variations ⁽²⁾	Utilised as at 30 November 2024	Unutilised IPO Proceeds	Timeframe for utilisation
	RM'000	RM'000	RM'000	RM'000	
Establishing new medical centres, satellite clinics and sales representative offices as follows:-					
(a) Two (2) specialist centres in Malaysia	32,000	21,400	-	21,400	
(b) Two (2) specialist centres in Indonesia	17,100	17,100	-	17,100	
(c) Four (4) satellite clinics in Indonesia	7,000	6,200	(1,218)	4,982	
(d) One (1) specialist centre in Laos / Cambodia	13,900	-	-	-	
(e) Two (2) sales representative offices in China	2,800	2,400	(649)	1,751	Within 36 months from the listing date
Expansion and upgrade of existing medical centres, facilities and corporate office	15,700	13,670	(620)	13,050	Within 36 months from the listing date
Establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China	-	27,500	(56)	27,444	Within 36 months from 21 August 2024
Research and development	2,200	2,200	(228)	1,972	Within 36 months from the listing date
General working capital	17,140	17,370	(6,934)	10,436	Within 36 months from the listing date
General corporate purposes	2,600	2,600	(317)	2,283	Within 36 months from the listing date
Defraying the listing expenses	6,200	6,200	(6,200) ⁽³⁾	-	Within 1 month from the listing date
Total	116,640	116,640	(16,222)	100,418	

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B7. Utilisation of Proceeds from the IPO (Cont'd)

Notes:

- (1) The utilisation of proceeds as disclosed above should be read in conjunction with the Prospectus dated 1 March 2024 in relation to its IPO and the announcement on variations of utilisation of IPO proceeds dated 21 August 2024.
- (2) The Company had varied the utilisation of IPO Proceeds to reallocate a total of RM27.73 million or approximately 23.77% for (i) establishing new medical centres, satellite clinics and sales representative offices and (ii) expansion and upgrade of existing medical centres, facilities and corporate office to (i) establishment / acquisition of medical centres, satellite clinics and sales representative offices in Asia including, but not limited to, Malaysia, Indonesia, Philippines and China as well as (ii) general working capital.
- (3) The listing expenses of RM5.89 million have been fully paid and the balance of RM0.31 million will be used as working capital of the Group. As of 30 November 2024, the Company had fully utilised the RM0.31 million for working capital purpose.

B8. Group Borrowings and Debt Securities

There were no group borrowings and debt securities as at 30 November 2024 and 31 May 2024.

B9. Material Litigation

There was no material litigation involving the Group as at 30 November 2024.

B10. Dividend Proposed or Declared

No dividend has been declared or proposed for the current financial quarter under review.

B11. Earnings per share

The basic earnings per share ("EPS") is calculated by dividing the profit for the period attributable to owners of the Company by weighted average number of ordinary shares of the Company during the financial period as follows:

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	30.11.2024 RM'000	30.11.2023 RM'000	30.11.2024 RM'000	30.11.2023 RM'000
Profit attributable to Owners of the Company (RM'000)	15,100	12,214	29,481	25,336
Weighted average number of ordinary shares (RM'000)	4,860,000	4,495,500	4,860,000	4,495,500
Basic/ Diluted EPS (sen)	0.31	0.27	0.61	0.56

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA SECURITIES (CONT'D)

B12. Notes to the Condensed Statement of Profit or Loss and Other Comprehensive Income

	<u>CURRENT QUARTER ENDED</u>		<u>CUMULATIVE PERIOD ENDED</u>	
	30.11.2024 RM'000	30.11.2023 RM'000	30.11.2024 RM'000	30.11.2023 RM'000
Profit before taxation is arrived at after charging/(crediting):				
Depreciation of equipment	616	1,064	1,216	2,317
Depreciation of right-of-use assets	676	797	1,368	1,400
Finance income	(1,425)	(523)	(2,949)	(926)
Finance costs	218	253	474	423
Equipment written off	-	#	-	#
Loss on disposal of equipment	1	#	1	#
Realised (gain)/loss in foreign exchange	(15)	13	2	22

– Less than RM1,000.

B13. Approval of Interim Financial Report

The interim financial report as set out above was authorised for issuance by the Board of Directors on 21 January 2025.